Indication: Non-Small Cell Lung Cancer (NSCLC)

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Previously treated c-Met+ patients

Sub-indication: Previously treated c-Met+ NSCLC

Line of Therapy: 2nd or 3rd line including no more than 1 line of prior cytotoxic chemo (c-Met+NSCLC)

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: AbbVie

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.